VTYX Ventyx Biosciences Inc.

22.31
+1.97  (+10%)
Previous Close 20.34
Open 20.55
52 Week Low 16.32
52 Week High 26
Market Cap $1,122,115,049
Shares 50,296,506
Float 26,104,556
Enterprise Value $1,035,433,932
Volume 149,691
Av. Daily Volume 161,167
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
VTX2735
Still’s disease, and juvenile idiopathic arthritis
Phase 1
Phase 1
IND clearance September 2021. Phase 1 clinical trial in healthy volunteers to initiate in the 4Q 2021.
VTX002
Ulcerative Colitis
Phase 2
Phase 2
Phase 1 trial in healthy volunteers was well tolerated at all doses tested with no serious adverse events. In addition, the drug showed a dose-dependent and steady-state reduction in ALC of up to 65%. Phase 2 trial planned initiated 4Q 2021.
VTX958
Crohn's disease, psoriatic arthritis, and lupus.
Phase 1
Phase 1
Phase 1 trial SAD portion completed and expect to initiated MAD portion in 4Q 2021 in healthy volunteers. Phase 2 Proof of concept (POC) trial expected 2H 2022.

Latest News

  1. ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences:

    • Event: 4th Annual Evercore ISI HealthCONx Conference
      Location: Virtual
      Date: Wednesday, December 1, 2021
      Time: 10:30-10:50 AM ET
    • Event: 33rd Annual Piper Sandler Healthcare Conference
      Location: Virtual
      Fireside Chat: A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22nd at 10:00am…

    ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences:

    • Event: 4th Annual Evercore ISI HealthCONx Conference

      Location: Virtual

      Date: Wednesday, December 1, 2021

      Time: 10:30-10:50 AM ET
    • Event: 33rd Annual Piper Sandler Healthcare Conference

      Location: Virtual

      Fireside Chat: A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22nd at 10:00am ET

    Members of the Ventyx management team will also host investor meetings during both conferences.

    Webcasts of both presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.

    About Ventyx

    Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

    Contacts:

    Investor Relations Contact:

    Patti Bank

    Managing Director

    ICR Westwicke

    (415) 513-1284



    Primary Logo

    View Full Article Hide Full Article
  2. Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets

    Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor

    Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3 million in gross proceeds, including full exercise of underwriters' option to purchase additional shares

    ENCINITAS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies…

    Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets

    Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor

    Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3 million in gross proceeds, including full exercise of underwriters' option to purchase additional shares

    ENCINITAS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx" or the "Company"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced financial results for the quarter ended September 30, 2021.

    "I am proud of our team's accomplishments as we work to build a leading immunology company that has three clinical stage programs," said Raju Mohan, Chief Executive Officer of Ventyx. "By selectively modulating key immune targets we have been able to generate differentiated drug candidates that have the potential to improve and expand treatment options for the millions of patients suffering from inflammatory diseases and autoimmune disorders. We believe our capital position, supplemented by funds raised via our October IPO, provides us the opportunity to advance our clinical pipeline towards multiple important data catalysts."

    Recent Corporate and Financial Highlights

    • On October 25, 2021, the Company announced the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,420,898 additional shares, at an initial public offering price of $16.00 per share. The aggregate net proceeds from the offering were approximately $158.8 million after deducting underwriting discounts, commissions and offering expenses.
    • Announced the appointment of Sheila Gujrathi, M.D. to the Board of Directors as Executive Chair and Jörn Drappa, M.D., Ph.D. as Chief Medical Officer. The Company also expanded the Board of Directors with the appointment of William White as an independent director and appointed Luisa Salter-Cid, Ph.D. as Chair of the Scientific Advisory Board.
    • On September 9, 2021, the Company closed a $51.0 million Series B convertible preferred stock financing round.

    Business Update

    • VTX958 (TYK2 Inhibitor): The Company's lead product candidate is VTX958, an allosteric, orally bioavailable TYK2 inhibitor designed to selectively inhibit TYK2 without detectable inhibition of other JAK isoforms. We believe VTX958 has the potential to address a broad range of immune-mediated diseases, such as psoriasis, psoriatic arthritis, Crohn's disease and lupus, each of which represent substantial market opportunities. We completed the single-ascending dose portion of our Phase 1 trial for VTX958 and initiated dosing in the MAD trial in the fourth quarter of 2021.
    • VTX002 (S1P1R Modulator): We are developing VTX002, an oral, selective Phase 2-ready sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). S1P1R is a clinically validated target. In our Phase 1 trial, VTX002 was well tolerated across all doses tested while producing dose-dependent reductions of circulating lymphocytes, a key biomarker of S1P1R modulator activity. Based on these data, we plan to initiate a Phase 2 randomized, placebo-controlled clinical trial in moderate-to-severe UC patients in the fourth quarter of 2021. We believe that this trial, along with an additional Phase 3 trial, may serve as the first of two pivotal trials required for registration.
    • VTX2735 (NLRP3 Inhibitor): We are developing a comprehensive portfolio of NLRP3 inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Our oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, targets systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases. We initiated dosing of VTX2735 in a Phase 1 trial in the fourth quarter of 2021.



    • Preclinical Pipeline: In addition to VTX2735, we are developing CNS-penetrant NLRP3 inhibitors and are currently evaluating candidates in the late stages of lead optimization. Based on preclinical and clinical evidence underscoring the pathogenic role of NLRP3 in neurodegenerative diseases, we believe CNS-penetrant NLRP3 inhibitors may have potential therapeutic utility for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis.

    Third Quarter 2021 Financial Results

    The presentation of the balances and amounts below for the third quarter 2021 reflect the financial results of Ventyx Biosciences, Inc. and its two wholly-owned subsidiaries, Oppilan Pharma, Ltd. and Zomagen Biosciences, Ltd., on a consolidated basis, as of the acquisition date of February 26, 2021. The presentation of the balances and amounts below for the third quarter 2020 reflect the financial results of Ventyx Biosciences, Inc. on a standalone basis.

    • Cash Position: Cash, cash equivalents and marketable securities were $142.0 million as of September 30, 2021. This does not include an additional $158.8 million in net proceeds from the Company's IPO in October 2021 after deducting underwriting discounts, commissions and offering expenses.
    • Research and Development (R&D) Expenses: R&D expenses were $10.5 million for the three months ended September 30, 2021, compared to $2.0 million for the same period in 2020.
    • General and Administrative (G&A) Expenses: G&A expenses were $2.2 million for the three months ended September 30, 2021, compared to $0.2 million for the same period in 2020.
    • Other Expenses: Other expenses were $0 for the three months ended September 30, 2021, compared to $4.9 million for the same period in 2020.
    • Net Loss: Net loss was $12.8 million for the three months ended September 30, 2021, compared to $7.2 million for the same period in 2020.

    About Ventyx Biosciences

    Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Our clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

    Forward-Looking Statements

    Ventyx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the anticipated timing of enrollment of clinical trials for Ventyx's product candidates; the expectation that the Phase 2 clinical trial for VTX002, along with an additional Phase 3 trial, may serve as the first of two pivotal trials required for registration; the potential of Ventyx's product candidates to address a broad range of immune-mediated diseases; the potential of CNS-penetrant NLRP3 inhibitors to treat Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis; plans to advance Ventyx's product candidates; and the expected timeframe for funding Ventyx's operating plan with current cash, cash equivalents and marketable securities. The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Ventyx's business, including, without limitation: potential delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the ongoing global outbreak of the COVID-19 pandemic, including clinical trial delays; the Company's dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Ventyx's clinical trials and preclinical studies for its product candidates; interim results do not necessarily predict final results and one or more of the outcomes may materially change as the trial continues and more patient data become available and following more comprehensive audit and verification procedures; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Ventyx's ability to obtain and maintain intellectual property protection for its product candidates; Ventyx may use its capital resources sooner than it expects; and other risks described in the Company's prior press releases and the Company's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the Company's final prospectus filed pursuant to Rule 424(b)(4) on October 21, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Ventyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor Relations Contact

    Patti Bank

    Managing Director

    ICR Westwicke

    (415) 513-1284



             
    Ventyx Biosciences, Inc.
    Condensed Consolidated Statements of Operations and Comprehensive Loss
    (in thousands, except share and per share amounts)
    (unaudited)
      Three Months Ended Nine Months Ended
      September 30, September 30,
       2021   2020   2021   2020 
    Operating expenses:        
    Research and development (includes related party amounts of $287, $179, $839 and $653, respectively) $10,545  $1,990  $44,657  $5,059 
    General and administrative (includes related party amounts of $0, $107, $116 and $328, respectively)  2,242   245   4,664   551 
    Total operating expenses  12,787   2,235   49,321   5,610 
             
    Loss from operations  (12,787)  (2,235)  (49,321)  (5,610)
             
    Other (income) expense:        
    Other (income) expense  (13)  1   31   1 
    Interest expense - related party     94   99   205 
    Change in fair value of notes and derivative - related party     4,825   11,051   5,656 
    Change in fair value of Series A tranche liability        5,476    
    Total other (income) expense  (13)  4,920   16,657   5,862 
    Net loss  (12,774)  (7,155)  (65,978)  (11,472)
    Deemed dividend        (1,552)   
    Net loss attributable to common shareholders $(12,774) $(7,155) $(67,530) $(11,472)
             
    Net loss $(12,774) $(7,155) $(65,978) $(11,472)
    Unrealized gain (loss) on marketable securities  6      6    
    Foreign currency translation  23      11    
    Comprehensive loss $(12,745) $(7,155) $(65,961) $(11,472)
             
    Net loss per share attributable to common shareholders, basic and diluted $(3.17) $(3.58) $(19.81) $(5.82)
    Shares used to compute basic and diluted net loss per share attributable to common shareholders  4,026,083   1,998,548   3,409,036   1,971,081 
             





          
    Ventyx Biosciences, Inc. 
    Selected Condensed Consolidated Balance Sheet Data 
    (in thousands) 
    (unaudited) 
          
      September 30, December 31, 
       2021   2020  
    Cash, cash equivalents and marketable securities $141,952  $244  
    Working capital  133,850   (1,158) 
    Total assets  148,709   245  
    Total liabilities  11,809   30,899  
    Accumulated deficit  (100,031)  (32,501) 
    Total convertible preferred stock and stockholders' deficit  136,900   (30,654) 
          

     



     

     



    Primary Logo

    View Full Article Hide Full Article
  3. ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,420,898 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering were approximately $174.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Ventyx. All shares in the offering were offered by Ventyx…

    ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,420,898 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering were approximately $174.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Ventyx. All shares in the offering were offered by Ventyx and began trading on the Nasdaq Global Select Market on October 21, 2021 under the ticker symbol "VTYX."

    Jefferies, Evercore ISI and Piper Sandler acted as joint book-running managers for the offering. LifeSci Capital also acted as an underwriter for the offering.

    Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on October 20, 2021. Copies of the registration statements related to the offering are available at www.sec.gov. The offering was made only by means of a prospectus, forming a part of the effective registration statements. Copies of the final prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ; and Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Ventyx

    Ventyx is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx's clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California.

    Contacts

    For more information, please contact:

    Investor Relations Contact:

    Patti Bank

    Managing Director

    Westwicke Partners

    (415) 513-1284



    Primary Logo

    View Full Article Hide Full Article
  4. ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced the pricing of its upsized initial public offering of 9,472,656 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Ventyx. In addition, Ventyx has granted the underwriters a 30-day option to purchase up to an additional 1,420,898 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts…

    ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced the pricing of its upsized initial public offering of 9,472,656 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Ventyx. In addition, Ventyx has granted the underwriters a 30-day option to purchase up to an additional 1,420,898 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ventyx, are expected to be approximately $151.5 million, excluding any exercise of the underwriters' option to purchase additional shares. The shares are expected to begin trading on the Nasdaq Global Select Market on October 21, 2021 under the ticker symbol "VTYX." The offering is expected to close on October 25, 2021, subject to the satisfaction of customary closing conditions.

    Jefferies, Evercore ISI and Piper Sandler are acting as joint book-running managers for the offering. LifeSci Capital is also acting as an underwriter for the offering.

    A registration statement relating to these securities became effective on October 20, 2021. The offering is made only by means of a prospectus, copies of which may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ; and Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Ventyx Biosciences

    Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx's clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. Ventyx is headquartered in Encinitas, California.  For more information about Ventyx, please visit www.ventyxbio.com.

    Investor Relations Contact

    Patti Bank

    Managing Director

    Westwicke Partners

    (415) 513-1284



    Primary Logo

    View Full Article Hide Full Article
View All Ventyx Biosciences Inc. News